Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cross-presentation enables dendritic cells to present on their MHC class I molecules antigenic peptides derived from exogenous material, through a mechanism that remains partly unclear. It is particularly efficient with long peptides, which are used in cancer vaccines. We studied the mechanism of long-peptide cross-presentation using human dendritic cells and specific CTL clones against melanoma Ags gp100 and Melan-A/MART1. We found that cross-presentation of those long peptides does not depend on the proteasome or the transporter associated with Ag processing, and therefore follows a vacuolar pathway. We also observed that it makes use of newly synthesized MHC class I molecules, through peptide exchange in vesicles distinct from the endoplasmic reticulum and classical secretory pathway, in an SEC22b- and CD74-independent manner. Our results indicate a nonclassical secretion pathway followed by nascent HLA-I molecules that are used for cross-presentation of those long melanoma peptides in the vacuolar pathway. Our results may have implications for the development of vaccines based on long peptides.

Original publication

DOI

10.4049/jimmunol.1501574

Type

Journal article

Journal

J Immunol

Publication Date

15/02/2016

Volume

196

Pages

1711 - 1720

Keywords

Antigen Presentation, Cell Line, Cells, Cultured, Cross-Priming, Dendritic Cells, Histocompatibility Antigens Class I, Humans, Peptides, Proteasome Endopeptidase Complex, T-Lymphocytes, Cytotoxic, Vacuoles, gp100 Melanoma Antigen